Influence of short-term selenium supplementation on the natural course of Hashimoto’s thyroiditis: clinical results of a blinded placebo-controlled randomized prospective trial

Journal of Endocrinological Investigation

Volumn 40, Issue 1, 2017, Pages 83-89

  Esposito, D ^a   Rotondi, M ^b   Accardo, G ^a   Vallone, G ^c   Conzo, G ^a   Docimo, G ^a   Selvaggi, F ^a   Cappelli, C ^d   Chiovato, L ^b   Giugliano, D ^a   Pasquali, D ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

Author keywords

1 selenomethionine; CXCL 10 levels; Hashimoto's thyroiditis; Thyroid echogenicity; Thyroid function

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; LIOTHYRONINE; PLACEBO; SELENOMETHIONINE; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROXINE; BIOLOGICAL MARKER; SELENIUM; THYROID HORMONE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ECHOGRAPHY; FEMALE; FREE THYROXINE INDEX; HASHIMOTO DISEASE; HUMAN; MAJOR CLINICAL STUDY; MINERAL SUPPLEMENTATION; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THYROID FUNCTION; ADOLESCENT; BLOOD; DIETARY SUPPLEMENT; IMMUNOASSAY; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS; DIETARY SUPPLEMENTS; FEMALE; HASHIMOTO DISEASE; HUMANS; IMMUNOASSAY; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SELENIUM; THYROID HORMONES; YOUNG ADULT;

EID: 85007564073     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-016-0535-4     Document Type: Article

References (33)

1. Almandoz J, Gharib H (2012) Hypothyroidism: etiology, diagnosis, and management. Med Clin N Am 96:203–221
2. Renzullo A, Accardo G, Esposito D, De Bellis A, Bizzarro A, Romano M, Federico A, Gravina AG, Conzo G, Pannone G, Faggiano A, Colao A, Pasquali D (2013) Hashimoto’s thyroiditis and entero-chromaffin-like cell hyperplasia: early detection and somatostatin analogue treatment. Eur J Inflamm 11:863–870
3. Wiebolt J, Achterbergh R, den Boer A, van der Leij S, Marsch E, Suelmann B, de Vries R, van Haeften TW (2011) Clustering of additional autoimmunity behaves differently in Hashimoto’s patients compared with Graves’ patients. Eur J Endocrinol 164:789–794
4. Caturegli P, De Remigis A, Chuang K, Dembele M, Iwama A, Iwama S (2013) Hashimoto’s thyroiditis: celebrating the centennial through the lens of the Johns Hopkins hospital surgical pathology records. Thyroid 23:142–150
5. Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C, Fallahi P (2014) Chemokine (C–X–C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 13:272–280
6. Rotondi M, Coperchini F, Pignatti P, Sideri R, Groppelli G, Leporati P, La Manna L, Magri F, Mariotti S, Chiovato L (2013) Interferon-γ and tumor necrosis factor-α sustain secretion of specific CXC chemokines in human thyrocytes: a first step toward a differentiation between autoimmune and tumor-related inflammation? J Clin Endocrinol Metab 98:308–313
7. Effraimidis G, Strieder TG, Tijssen JG, Wiersinga WM (2011) Natural history of the transition from euthyroidism to overt autoimmune hypo- or hyperthyroidism: a prospective study. Eur J Endocrinol 164:107–113
8. Drutel A, Archambeaud F, Caron P (2013) Selenium and the thyroid gland: more good news for clinicians. Clin Endocrinol (Oxf) 78:155–164
9. Gärtner R, Gasnier BC (2003) Selenium in the treatment of autoimmune thyroiditis. BioFactors 19:165–170
10. Turker O, Kumanlioglu K, Karapolat I, Dogan I (2006) Selenium treatment in autoimmune thyroiditis: 9 month follow-up with variable doses. J Endocrinol 190:151–156
11. Negro R, Greco G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H (2007) The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. J Clin Endocrinol Metab 92:1263–1268
12. Nacamulli D, Mian C, Petricca D, Lazzarotto F, Barollo S, Pozza D, Masiero S, Faggian D, Plebani M, Girelli ME, Mantero F, Betterle C (2010) Influence of physiological dietary selenium supplementation on the natural course of autoimmune thyroiditis. Clin Endocrinol (Oxf) 73:535–539
13. Krysiak R, Okopien B (2011) The effect of levo-thyroxine and selenomethionine on lymphocyte and monocyte cytokine release in women with Hashimoto’s thyroiditis. J Clin Endocrinol Metab 96:2206–2215
14. Krysiak R, Okopien B (2012) Haemostatic effects of levo-thyroxine and selenomethionine in euthyroid patients with Hashimoto’s thyroiditis. Thromb Haemost 108:973–980
15. Petricca D, Nacamulli D, Mian C, Mantero F, Cavedon E, Girelli ME, Betterle C (2012) Effects of selenium supplementation on the natural course of autoimmune thyroiditis: a short review. J Endocrinol Investig 35:419–424
16. Köhrle J (2015) Selenium and the thyroid. Curr Opin Endocrinol Diabetes Obes 22:392–401
17. van Zuuren EJ, Albusta AY, Fedorowicz Z, Carter B, Pijl H (2013) Selenium supplementation for Hashimoto’s thyroiditis. Cochrane Database Syst Rev 6:D010223
18. Koprowski R, Korzyńska A, Wróbel Z, Zieleźnik W, Witkowska A, Małyszek J, Wójcik W (2012) Influence of the measurement method of features in ultrasound images of the thyroid in the diagnosis of Hashimoto’s disease. Biomed Eng Online 11:91
19. De Fusco C, Nettore IC, Colao A, Macchia P (2013) Selenium in the thyroid: physiology and pathology. Rev Endocrinol Metab CIC Edizioni Int 1:34–40
20. Rayman MP (2000) The importance of selenium to human health. Lancet 356:233–241
21. Rayman MP (2012) Selenium and human health. Lancet 379:1256–1268
22. Wu Q, Rayman MP, Lv H (2015) Low population selenium status is associated with increased prevalence of thyroid disease. J Clin Endocrinol Metab 100:4037–4047
23. Panicker V (2011) Genetics of thyroid function and disease. Clin Biochem Rev 32:165–175
24. Olivieri O, Girelli D, Azzini M, Stanzial AM, Russo C, Ferroni M, Corrocher R (1995) Low selenium status in the elderly influences thyroid hormones. Clin Sci 89:637–642
25. Gärtner R, Gasnier BC, Dietrich JW, Krebs B, Angstwurm MW (2002) Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J Clin Endocrinol Metab 87:1687–1691
26. Bratakos MS, Kanaki HC, Vasiliou-Waite A, Ioannou PV (1990) The nutritional selenium status of healthy Greeks. Sci Total Environ 91:161–176
27. Duntas LH, Mantzou E, Koutras DA (2003) Effects of a 6 month treatment with selenomethionine in patients with autoimmune thyroiditis. Eur J Endocrinol 148:389–393
28. Mazokopakis EE, Papadakis JA, Papadomanolaki MG, Batistakis AG, Giannakopoulos TG, Protopapadakis EE, Ganotakis ES (2007) Effects of 12 months treatment with l-selenomethionine on serum anti-TPO levels in patients with Hashimoto’s thyroiditis. Thyroid 17:609–612
29. de Farias CR, Cardoso BR, de Oliveira GM, de Mello Guazzelli IC, Catarino RM, Chammas MC, Cozzolino SM, Knobel M (2015) A randomized-controlled, double-blind study of the impact of selenium supplementation on thyroid autoimmunity and inflammation with focus on the GPx1 genotypes. J Endocrinol Invest 38:1065–1074
30. Toulis KA, Anastasilakis AD, Tzellos TG, Goulis DG, Kouvelas D (2010) Selenium supplementation in the treatment of Hashimoto’s thyroiditis: a systematic review and a meta-analysis. Thyroid 20:1163–1173
31. Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, European Group on Graves’ Orbitopathy (EUGOGO) (2016) The 2016 European Thyroid Association/European Group on Graves’ orbitopathy guidelines for the management of graves’ orbitopathy. Eur Thyroid J 5:9–26
32. Pilli T, Cantara S, Schomburg L, Cenci V, Cardinale S, Heid EC, Kühn EC, Cevenini G, Sestini F, Fioravanti C, D’Hauw G, Pacini F (2015) IFNγ-inducible chemokines decrease upon selenomethionine supplementation in women with euthyroid autoimmune thyroiditis: comparison between two doses of selenomethionine (80 or 160 μg) versus Placebo. Eur Thyroid J 4:226–233
33. Fallahi P, Ferrari SM, Elia G, Nasini F, Colaci M, Giuggioli D, Vita R, Benvenga S, Ferri C, Antonelli A (2016) Novel therapies for thyroid autoimmune diseases. Expert Rev Clin Pharmacol 9:853–861